Evidence map›Paper›PMID 35304540›Full record

ArticleScientific reports2022

Neurofunctional and neuroimaging readouts for designing a preclinical stem-cell therapy trial in experimental stroke.

Chloé Dumot, Chrystelle Po, Lucille Capin, Violaine Hubert, Elodie Ong, Matthieu Chourrout, Radu Bolbos, Camille Amaz, Céline Auxenfans, Emmanuelle Canet-Soulas and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Chloé DumotUniv Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, INSA Lyon, Université Claude Bernard Lyon 1, Université Claude Bernard Lyon 1, Lyon, France.
Chrystelle PoICube, Université de Strasbourg, CNRS, UMR 7357, Strasbourg, France.
Lucille CapinTissue and Cell Bank, HCL, Lyon, France.
Violaine HubertUniv Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, INSA Lyon, Université Claude Bernard Lyon 1, Université Claude Bernard Lyon 1, Lyon, France.
Elodie OngUniv Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, INSA Lyon, Université Claude Bernard Lyon 1, Université Claude Bernard Lyon 1, Lyon, France.
Matthieu ChourroutUniv Lyon 1, Lyon Neurosciences Research Center, CNRS UMR5292, Inserm U1028, Université Claude Bernard Lyon 1, Université Claude Bernard Lyon 1, Lyon, France.
Radu BolbosCermep, Lyon, France.
Camille AmazClinical Investigation Center, CIC 1407, HCL, Louis Pradel Hospital, Lyon, France.
Céline AuxenfansHospices Civils de Lyon, Lyon, France.
Emmanuelle Canet-SoulasUniv Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, INSA Lyon, Université Claude Bernard Lyon 1, Université Claude Bernard Lyon 1, Lyon, France.
Claire RomeInserm, U1216, Grenoble Institut des Neurosciences (GIN), Université Grenoble Alpes, 38000 , Grenoble, France.
Fabien ChauveauUniv Lyon 1, Lyon Neurosciences Research Center, CNRS UMR5292, Inserm U1028, Université Claude Bernard Lyon 1, Université Claude Bernard Lyon 1, Lyon, France.
Marlène WiartUniv Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, INSA Lyon, Université Claude Bernard Lyon 1, Université Claude Bernard Lyon 1, Lyon, France. marlene.wiart@univ-lyon1.fr.
Hospices Civils de Lyon · FRCentre National de la Recherche Scientifique · FRInserm · FRCentre d'Exploration et de Recherche Médicale par Emission de Positons · FRGrenoble Institute of Neurosciences · FRInstitut National des Sciences Appliquées de Lyon · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the aim of designing a preclinical study evaluating an intracerebral cell-based therapy for stroke, an observational study was performed in the rat suture model of ischemic stroke. Objectives were threefold: (i) to characterize neurofunctional and imaging readouts in the first weeks following transient ischemic stroke, according to lesion subtype (hypothalamic, striatal, corticostriatal); (ii) to confirm that intracerebral administration does not negatively impact these readouts; and (iii) to calculate sample sizes for a future therapeutic trial using these readouts as endpoints. Our results suggested that the most relevant endpoints were side bias (staircase test) and axial diffusivity (AD) (diffusion tensor imaging). Hypothalamic-only lesions did not affect those parameters, which were close to normal. Side bias in striatal lesions reached near-normal levels within 2 weeks, while rats with corticostriatal lesions remained impaired until week 14. AD values were decreased at 4 days and increased at 5 weeks post-surgery, with a subtype gradient: hypothalamic < striatal < corticostriatal. Intracerebral administration did not impact these readouts. After sample size calculation (18-147 rats per group according to the endpoint considered), we conclude that a therapeutic trial based on both readouts would be feasible only in the framework of a multicenter trial.

Indexed as

Ischemic StrokeStrokeAnimalsCell- and Tissue-Based TherapyDiffusion Magnetic Resonance ImagingDiffusion Tensor ImagingRats

Identifiers

PMID35304540
PMCPMC8933390
OpenAlexW4220924458

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.